Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

			01.26	ection 3	50(H) OF THE	riives	sunen	t Cor	прапу Аст о	1 1940						
Name and Address of Reporting Person* Betz Stephen F.				2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX]								5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owner Officer (give title Other (spec			Owner	
(Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC. 10222 BARNES CANYON ROAD, BLDG 2				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022							Chief Scientific Officer					
			4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) X Form Form	′			
	Table	I - Non-Deri	vative \$	Secui	rities Ad	quir	red,	Dis	posed of	, or Be	nefici	ally Own	ed			
Date				Execution Date,		, Tr	Transaction Disposed (Code (Instr. 5)				nd Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							ode	v	Amount	(A) or (D)	Price	Transa	ction(s)		(111311. 4)	
Common stock 01/03/2			3/2022	2022		S	S ⁽¹⁾		7,168	D	\$28.	.02 13	3,043	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
tive Conversion Date Execution Date, ty or Exercise (Month/Day/Year) if any		Code (Transaction of Code (Instr. Derivative		e (Me	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities S		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficiall Owned Following Reported	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
	(Fi INETICS P BARNES CA EGO CA (St Security (Ins 1 stock	(First) (NINETICS PHARMACEUTICS PHARMACEUTICS ARNES CANYON ROAD, EGO CA 9 (State) (Z Table Security (Instr. 3) 1 stock Tal 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) INETICS PHARMACEUTICALS, INC. BARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Deri Security (Instr. 3) 2. TransDate (Month) I stock Table II - Derivity (e.g., Conversion or Exercise Price of Derivative (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3A. Derivative (Month/Day/Year) (Month/Day/Year)	Table I - Non-Derivative Security (Instr. 3) Table II - Derivative Security (Instr. 3) Table II - Derivative Security (Month/Day/Year) Table II - Derivative Security (Month/Day/Year)	2. Issuer Na Crinetic	2. Issuer Name and T Crinetics Pharm Crinetics Pharm 2. Issuer Name and T Crinetics Pharm 3. Date of Earliest Tra 01/03/2022 4. If Amendment, Date (State) (Zip) Table I - Non-Derivative Securities Acc (Month/Day/Year) Table II - Derivative Securities Acc (e.g., puts, calls, warrant: 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date if any (Month/Day/Year) 5. Number Ocde (Instr. 8) 5. Number Ocde (Instr. 8) 5. Number Ocde (Instr. 8)	Table I - Non-Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Security Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Security) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Security) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Security) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Security) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4)	2. Issuer Name and Ticker or Tra Crinetics Pharmaceutic 3. Date of Earliest Transaction (M 01/03/2022 4. If Amendment, Date of Original (State) (Zip) Table I - Non-Derivative Securities Acquired, (Month/Day/Year) Table II - Derivative Securities Acquired, Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities Acquired, D (e.g., puts, calls, warrants, option 2. Conversion or Exercise Price of Derivative Securities Acquired (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8) 5. Number of Porivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	2. Issuer Name and Ticker or Trading Crinetics Pharmaceuticals, (First) (Middle) INETICS PHARMACEUTICALS, INC. BARNES CANYON ROAD, BLDG 2 EGO CA 92121 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of (D) Privative Security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (D) Privative Securities Acquired (Month/Day/Year) 3. Date of Earliest Transaction (Month/D1/03/2022) 4. If Amendment, Date of Original Filed Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) 3. Transaction Code (Instr. 8) Code V Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4) A. Deemed Execution Date, if any (Month/Day/Year) 2. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4)	Crinetics Pharmaceuticals, Inc. Crin	Crinetics Pharmaceuticals, Inc. [CRNX]	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX] 5.	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship (Check all applied of the plane) 5. All and plane 5. Relationship (Check all applied of the plane) 5. Relationship (Check all applied of the plane)	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship of Reporting Person* (Check all applicable) Director Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship of Reporting Person* (Check all applicable) Director Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship of Reporting Person* (Check all applicable) Director Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship of Reporting Person* (Check all applicable) Director Crinetics Pharmaceuticals, Inc. [CRNX] 5. Relationship of Reporting Person* (Check all applicable) (Check all applicable) Check all applicable) Check all applicables (Check all applicable) Check all applicables (Check all applicables) (Check all applic	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. CRNX S. Relationship of Reporting Person(s) to Crinetics Pharmaceuticals, Inc. CRNX S. Director 10% of Other below Chief Scientific Officer 10% of Other below Chief Scientific Officer 10% of Other below Chief Scientific Officer Chief Scien	

Date Exercisable

Expiration Date

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

Remarks:

/s/ Marc Wilson, as attorneyin-fact

Number

01/06/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)